Keros Therapeutics (KROS) EBITDA (2019 - 2025)

Keros Therapeutics has reported EBITDA for 7 years, with the latest figure at -$29.3 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 45.04% year-over-year to -$29.3 million; the trailing twelve-month figure through Dec 2025 stood at $67.6 million (up 132.05% YoY), and the FY2025 full-year result was $67.6 million, up 132.05% from the prior year.
• EBITDA for Q4 2025 stood at -$29.3 million, down from -$15.4 million in the prior quarter.
• The five-year high for EBITDA was $152.0 million in Q1 2025, with the low at -$58.7 million in Q3 2024.
• Historically, EBITDA has averaged -$24.2 million across 5 years, with a median of -$31.3 million in 2022.
• Annual changes were most pronounced in 2022 — EBITDA sank 556.8% — and 2025, when it surged 413.59%.
• Keros Therapeutics' EBITDA stood at -$4.9 million in 2021, then slumped by 556.8% to -$32.0 million in 2022, then slumped by 45.35% to -$46.5 million in 2023, then retreated by 14.64% to -$53.3 million in 2024, then soared by 45.04% to -$29.3 million in 2025.
• The last three EBITDA figures came in at -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025), per Business Quant data.